Merck joins hunt for Ebola vaccine

It's a bit of a circuitous route, but Merck has now licensed the Canadian developed Ebola vaccine. I feel bad that the link isn't back to a Canadian firm, but sometimes you need the might that only a giant can bring.

The Public Health Agency of Canada originally developed rVSV-EBOV, the compound it licensed to NewLink, and is already in first-phase human trials. But NewLink needed Merck’s size to fully research, develop, manufacture, and distribute any potential medicine. The Canadian agency retains rights in the NewLink-Merck deal, but it also represents the greater focus of governments of developed nations, which fear the spread of the virus.